Abstract: Provided are methods of treating cancer or increasing, enhancing, or stimulating an immune response with non-competitive, agonist anti-OX40 antibodies and antigen-binding fragments thereof that bind to human OX40 (ACT35, CD 134, or TNFRSF4), in combination with an anti-PD 1 or with an anti-PDL 1 antibody.

Abstract: By the abovementioned technical solutions, the present disclosure provides optimizing a vector autoregressive model conforming to structural constraints of sparsity and acyclicity. A regularization term is introduced to the model to impose the sparsity structural constraint such that most off-diagonal coefficients of an autoregressive coefficient matrix are forced to zero values. One or more penalty terms are introduced to the model to impose the acyclicity structural constraint such that coefficients of the main diagonal are not causally self-related. The resulting model is then reformulated for computation as an augmented Lagrangian function, and further computed for different parameters in alternating iterations to make the computations tractable and within magnitude and precision limits of digital computers.

Abstract: The present disclosure provides methods of treating cancer with non-competitive, agonist anti-OX40 antibodies and antigen-binding fragments thereof that bind to human OX40 (ACT35, CD134, or TNFRSF4), in combination with a multi-kinase inhibitor.

Abstract: Provided are methods of treating cancer with non-competitive, agonist anti-OX40 antibodies and antigen-binding fragments thereof that bind to human OX40 (ACT35, CD134, or TNFRSF4), in combination with a PI3K (phosphatidylinositol-4,5-bis-phosphate 3-kinase) delta inhibitor.

Abstract: Provided are methods of treating cancer or increasing, enhancing, or stimulating an immune response with non-competitive, agonist anti-OX40 antibodies and antigen-binding fragments thereof that bind to human OX40 (ACT35, CD134, or TNFRSF4), in combination with an anti-TIGIT antibody or fragment thereof.

Abstract: Provided are methods of treating cancer or increasing, enhancing, or stimulating an immune response with non-competitive, agonist anti-OX40 antibodies and antigen-binding fragments thereof that bind to human OX40 (ACT35, CD134, or TNFRSF4), in combination with an anti-TIM3 antibody or antigen binding fragment thereof.

Abstract: Provided are methods of treating cancer with non-competitive, anti-OX40 antibodies and antigen-binding fragments thereof that bind to human OX40 (ACT35, CD134, or TNFRSF4), in combination with a chemotherapeutic agent.

Abstract: A time series distance estimation system may receive two time series and estimate a distance or a degree of dissimilarity between the two time series. The system may calculate a time warp function for the two time series, and perform a trend filtering alternately in a multi-level framework to further accelerate the speed of computation.

Abstract: Time series decomposition method and system are provided. Time series data including at least a seasonality component is received. A noise removal filter may be applied to the time series data. Furthermore, a trend component and the seasonality component are extracted from the time series data. A residual component may subsequently be extracted from the time series data based on the trend component and the seasonality component. Anomaly detection may then be performed on the trend component or the residual component to determine whether an anomaly exists in the time series data.

Abstract: By the abovementioned technical solutions, the present disclosure provides optimizing a vector autoregressive model conforming to structural constraints of sparsity and acyclicity. A regularization term is introduced to the model to impose the sparsity structural constraint such that most off-diagonal coefficients of an autoregressive coefficient matrix are forced to zero values. One or more penalty terms are introduced to the model to impose the acyclicity structural constraint such that coefficients of the main diagonal are not causally self-related. The resulting model is then reformulated for computation as an augmented Lagrangian function, and further computed for different parameters in alternating iterations to make the computations tractable and within magnitude and precision limits of digital computers.

Abstract: Time series decomposition method and system are provided. Time series data including at least a seasonality component is received. A noise removal filter may be applied to the time series data. Furthermore, a trend component and the seasonality component are extracted from the time series data. A residual component may subsequently be extracted from the time series data based on the trend component and the seasonality component. Anomaly detection may then be performed on the trend component or the residual component to determine whether an anomaly exists in the time series data.

Abstract: Methods and systems for object sorting are provided. One method includes: recognizing object information of a plurality of objects in motion; obtaining destination information of the plurality of objects according to the object information, wherein the destination information of the plurality of objects comprises a plurality of destinations of the plurality of objects; determining a plurality of colors corresponding to the plurality of objects according to the plurality of destinations of the plurality of objects; and distinguishing the plurality of objects by using a plurality of lights of the plurality of colors respectively, to sort the plurality of objects in motion having the plurality of destinations.

Abstract: Methods and systems for correcting an error of a GPS signal are provided. The method includes receiving a request for positioning service from a computing device at a location; estimating a Total Electron Content (vTEC) value associated with the location of the object based at least in part on a plurality of vTEC values of a plurality of ground stations equipped with a plurality of GPS receivers, the vTEC value being estimated based on an estimator that is trained using a filter-reweight-retrain robust algorithm; and sending information of the estimated vTEC value to the computing device to allow the computing device to correct an error of a GPS signal received by the computing device, the error of the GPS signal being associated with an ionospheric delay.

Abstract: Disclosed herein are recombinant protein scaffolds and recombinant multifunctional protein scaffolds for use in producing antigen-binding proteins In addition, nucleic acids encoding such recombinant protein scaffolds, recombinant multifunctional protein scaffolds, and antigen-binding proteins are provided Vectors and cells useful for expression of the described proteins are also provided, as are methods of use.

Abstract: The present invention relates to the diagnosis and treatment of cancer, and specifically to a method of diagnosing the presence, status or metastasis of cancer by detecting plasma Hsp90? having the amino acid sequence of SEQ ID NO:1 as a tumor marker. In addition, the present invention also relates to a method for the treatment of cancer and metastasis.

Abstract: Disclosed herein are recombinant protein scaffolds and recombinant multifunctional protein scaffolds for use in producing antigen-binding proteins In addition, nucleic acids encoding such recombinant protein scaffolds, recombinant multifunctional protein scaffolds, and antigen-binding proteins are provided Vectors and cells useful for expression of the described proteins are also provided, as are methods of use.

Abstract: Disclosed herein are recombinant protein scaffolds and recombinant multifunctional protein scaffolds for use in producing antigen-binding proteins In addition, nucleic acids encoding such recombinant protein scaffolds, recombinant multifunctional protein scaffolds, and antigen-binding proteins are provided Vectors and cells useful for expression of the described proteins are also provided, as are methods of use.

Abstract: A method of determining whether a subject has cancer or has a risk of getting cancer comprises: detecting the concentration of Hsp90a in a blood sample of the subject; and if the concentration reaches or exceeds a preset threshold value, determining that the subject has cancer or has a risk of getting cancer, where the threshold value is selected from a range from 50 ng/ml to 120 ng/ml; for example, the threshold value may be 50, 53, 56, 62, 63, 64, 67, 72, 82, 85 or 117 ng/ml, and a numerical value within the ±15% range of the threshold value is regarded having equivalent significance for determination.

Abstract: The present invention relates to the diagnosis and treatment of cancer, and specifically to a method of diagnosing the presence, status or metastasis of cancer by detecting plasma Hsp90? having the amino acid sequence of SEQ ID NO:1 as a tumor marker. In addition, the present invention also relates to a method for the treatment of cancer and metastasis.

Abstract: The present invention relates to the diagnosis and treatment of cancer, and specifically to a method of diagnosing the presence, status or metastasis of cancer by detecting plasma Hsp90? having the amino acid sequence of SEQ ID NO:1 as a tumor marker. In addition, the present invention also relates to a method for the treatment of cancer and metastasis.